During the following 26 weeks of treatment (extension phase), discontinuations as a result of adverse events occurred in 2.4% of patients in the T-T group (patients treated with tesamorelin for Week 0-26 and with tesamorelin for Week 26-52) and 5.2% of patients in the T-P group (patients treated with tesamorelin for Week 0-26 and with placebo for Week 26-52)
10:1719-1726 (2015) Shibai A, Takahashi Y, Ishizawa Y, Motooka D, Nakamura S, Ying B-W, Tsuru S
By 2014 the two scientists had managed to achieve their goal
About 42 drug manufacturers, including smaller ones, are expected to launch products under more than 50 brand names this year, said Sheetal Sapale, a researcher at market data firm Pharmarack
At the moment, there is no standard protocol for the dosage of PT-141 that would apply to all scientific experiments